Aardvark Therapeutics (AARD) Institutional Ownership $11.26 +0.06 (+0.54%) As of 08/14/2025 04:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Aardvark Therapeutics (NASDAQ:AARD)Number ofInstitutional Buyers(last 12 months)9TotalInstitutional Inflows(last 12 months)$42.64MNumber ofInstitutional Sellers(last 12 months)0 Get AARD Insider Trade Alerts Want to know when executives and insiders are buying or selling Aardvark Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data AARD Institutional Buying and Selling by Quarter Aardvark Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/14/2025MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.3,091$42K0.0%N/A0.014% 8/13/2025 New York State Common Retirement Fund7,300$99K0.0%N/A0.034% 8/8/2025 Geode Capital Management LLC136,927$1.85M0.0%+129.7%0.631% 6/27/2025Goldman Sachs Group Inc.20,311$153K0.0%N/A0.094% 5/16/2025Goldman Sachs Group Inc.20,311$153K0.0%N/A0.094% 5/16/2025Cormorant Asset Management LP800,189$6.01M0.5%N/A3.688% 5/16/2025Adage Capital Partners GP L.L.C.250,000$1.88M0.0%N/A1.152% 5/15/2025Braidwell LP500,000$3.76M0.1%N/A2.305% 5/14/2025 Walleye Capital LLC11,730$88K0.0%N/A0.054% 5/8/2025 Decheng Capital LLC3,917,299$29.42M8.3%N/A18.055% (Data available from 1/1/2016 forward) AARD Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of AARD shares? During the previous two years, 9 institutional investors and hedge funds held shares of Aardvark Therapeutics. The most heavily invested institutionals were Decheng Capital LLC ($29.42M), Cormorant Asset Management LP ($6.01M), Braidwell LP ($3.76M), Adage Capital Partners GP L.L.C. ($1.88M), Geode Capital Management LLC ($1.85M), Goldman Sachs Group Inc. ($153K), and New York State Common Retirement Fund ($99K).Learn more on Aardvark Therapeutics' institutional investors. Which institutional investors have been buying Aardvark Therapeutics' stock? Of the 9 institutional investors that purchased Aardvark Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Decheng Capital LLC ($3.92M), Cormorant Asset Management LP ($800.19K), Braidwell LP ($500K), Adage Capital Partners GP L.L.C. ($250K), Geode Capital Management LLC ($77.33K), Goldman Sachs Group Inc. ($40.62K), and Walleye Capital LLC ($11.73K). How much institutional buying is happening at Aardvark Therapeutics? Institutional investors have bought a total of 5,607,558 shares in the last 24 months. This purchase volume represents approximately $42.64M in transactions. Related Companies VERV Major Shareholders LENZ Major Shareholders PRAX Major Shareholders RCUS Major Shareholders AVXL Major Shareholders GPCR Major Shareholders SYRE Major Shareholders CRON Major Shareholders ELVN Major Shareholders AKBA Major Shareholders This page (NASDAQ:AARD) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access